There is an increasing need for translational studies identifying molecular targets contributing to atherosclerotic plaque destabilization. Local molecular plaque markers that are related to plaque vulnerability may hold predictive value to identify patients who are at increased risk to suffer from cardiovascular events. Animal studies revealed that adipocyte fatty acid binding protein (FABP4) is associated with the progression of atherosclerosis; however, FABP4 expression studies in human atherosclerotic plaques are lacking. We investigated FABP4 expression in carotid atherosclerotic lesions in relation to plaque composition and future cardiovascular events.
Introduction
The vulnerable atherosclerotic plaque is recognized as the pathological substrate of acute ischaemic cardiovascular events, such as myocardial infarction and stroke. There is a need for drugs that prevent plaque growth and destabilization of the atherosclerotic plaques. In addition, biomarkers are required that can demonstrate drug efficacy and that are predictive of the progression of atherosclerotic disease in order to stratify patients who have an increased risk to suffer from cardiovascular events Animal studies have shown that adipocyte fatty acid binding protein (FABP4) is associated with atherosclerotic plaque formation and vulnerable plaque features. 1 -7 In addition, FABP4 has been described as a potential pharmaceutical target to intervene in atherosclerotic plaque progression in vivo. 8, 9 However, except a histochemical FABP4 expression study, 10 FABP4 expression studies have hardly been performed in atherosclerotic diseased human specimens. In the current study, we correlated FABP4 expression levels to carotid artery plaque characteristics.
Since atherosclerotic plaque composition is associated with cardiovascular events and correlates between different arterial territories, 11 -14 we assume that plaque composition of a single atherosclerotic plaque provides molecular information on the general stability of atherosclerotic plaques throughout the vascular system and, subsequently, systemic cardiovascular outcome. 15 Therefore, we introduce an innovative concept in biomarker validation. We conducted a prognostic study to investigate the predictive value of local plaque FABP4 levels for the occurrence of cardiovascular events originating from all vascular territories during follow-up. Although expression studies of atherosclerotic plaques in relation to cardiovascular outcome support an evident causal relationship, plaque specimens are relatively difficult to collect and are therefore a less suitable source for biomarker detection. Therefore, we performed an additional prognostic serological study to examine the association of serum FABP4 levels with the cardiovascular outcome. Previous animal pharmaceutical intervention studies suggest that FABP4 antagonists result in reduced atherosclerotic plaque development. The outcome of the current human plaque expression study including a longitudinal study design may help to validate the clinical relevance of FABP4 as a pharmaceutical target in atherosclerotic disease progression.
Methods

Athero-Express biobank
Athero-Express is an ongoing biobank study with a longitudinal study design, comprising atherosclerotic plaques obtained from patients who underwent carotid endarterectomy (CEA). The study design has been reported previously. 16 Plaques are collected during CEA and processed according to a standardized protocol. After the operation, the patients undergo a 3-year clinical follow-up. All patients undergoing CEA in the two participating centres (St Antonius Hospital Nieuwegein and University Medical Center Utrecht) are asked to participate in the study. The medical ethics board of both participating hospitals approved the study, and all participants provided written informed consent. For the present study, we included 561 plaques from consecutive patients operated between 24 March 2002 and 28 February 2006.
Patient population
The indication to perform CEA was based on the outcomes of the Asymptomatic Carotid Atherosclerosis Study (ACAS) and Asymptomatic Carotid Surgery Trial (ACST) for asymptomatic patients and the North American Symptomatic Carotid Endarterectomy Trial (NASCET) and European Carotid Surgery Trial (ECST) for symptomatic patients. 17 -21 All indications for surgery were reviewed in a multidisciplinary vascular team. Pre-operatively and postoperatively, patients were examined by a neurologist to document the cerebrovascular symptom status and to record any new neurological deficits after CEA. Percentage stenosis of both carotid arteries was recorded with duplex ultrasound pre-operatively following internationally accepted guidelines. The patients filled questionnaires concerning cardiovascular risk factors, medical history, and medication use. Clinical data were obtained from patient charts. The definitions of hypertension and hypercholesterolaemia were restricted to those cases requiring medical treatment. Patients who suffered from stroke, transient ischaemic attack (TIA) or amaurosis fugax (AFX) were considered as being symptomatic. Patients operated due to a significant stenosis (.70%) without symptoms were considered asymptomatic. In the comparison of FABP expression levels in symptomatic lesions vs. asymptomatic lesions, AFX patients were analysed separately, since we observed in a previous study that the plaque composition from AFX lesions corresponds strongly with the composition as observed in asymptomatic lesions.
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Follow-up and outcome
Follow-up protocol
After CEA, all patients underwent a clinical follow-up. Patients received a questionnaire asking whether they had experienced any vascular event or had been hospitalized in the past year at 1, 2, and 3 years following surgery. If any of the questions was answered positively, further research was performed to define the outcome event. Following a standard scheme, discharge letters and, if needed, laboratory measurements and results of additional studies such as electrocardiograms or imaging studies were collected from the institution where the potential event occurred. If patients did not respond to the follow-up questionnaire, the general practitioner was contacted. Per potential outcome event, all available information was validated by two independent members of the outcome assessment committee. If the two members disagreed if the criteria for the outcome event were met, a third opinion was requested.
Definition of outcome
The primary outcome was defined as any vascular event or vascular intervention. This composite endpoint included any death of presumed vascular origin (fatal stroke, fatal myocardial infarction, sudden death, and other vascular death), non-fatal stroke, non-fatal myocardial infarction, and any arterial vascular intervention that had not already been planned at the time of inclusion (e.g. carotid surgery or angioplasty, coronary bypass, percutaneous coronary intervention, peripheral vascular surgery or angioplasty). In addition, we distinguished two subgroups regarding the clinical outcome in different vascular territories; Major clinical outcome was defined as (non)-fatal myocardial infarction, (non)-fatal stroke, coronary bypass, coronary intervention, and sudden death. Peripheral interventions comprised leg amputation and peripheral arterial intervention during follow-up that had not been planned at the time of inclusion.
Tissue examination Determination of plaque phenotype
According to a standardized protocol, the plaque was divided into segments of 5 mm thickness along the longitudinal axis. 16 The segment with the greatest plaque burden was considered as the culprit lesion and subjected to histological examination as described previously. Macrophage (CD68) and smooth muscle cell (SMC) (alfa-actin) stains were primarily quantitatively scored using computerized analyses Plaque haemorrhages, including both luminal thrombosis and intraplaque haematoma, were examined in H&E and fibrin stainings and rated as being 'absent' or 'present'. The histological examinations were performed by two independent observers. The observers were blinded for clinical outcome. The histological examinations showed good inter-observer and intra-observer reproducibility on different items. 24 The semi-quantitative and quantitative scorings revealed an excellent correlation.
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Fatty acid binding protein immunohistochemical staining To confirm co-localization of FABP4 and CD68-positive cells, we performed double staining as follows. Slides were boiled in citrate buffer, blocked with 10% normal goat serum and incubated with rat anti-FABP4 monoclonal antibody (1:200; R&D Systems), rabbit anti-rat IgG (1:750), and Powervision poly-HRP-anti-rabbit IgG (Immunologic), and treated with sodium acetate buffer containing 3-amino-9-ethyl carbazole ( Figure 1C ) to visualize FABP4 in comparison with New Fuchsin Alkaline Phosphatase Substrate ( Figure 1B) . Owing to the technical design of the double immunohistochemical staining, it was not possible to use New Fuchsin in double staining ( Figure 1C) . Therefore, FABP4 was stained with a different colour in Figure 1C . In addition, we made a picture of the double staining at a very high magnification to differentiate between the different CD68 and FABP4 stainings.
Subsequently, slides were incubated with mouse anti-CD68 monoclonal antibody (1:400; Novocastra, Newcastle upon Tyne, UK) and Powervision poly-AP-anti-mouse IgG (Immunologic) and treated with Fast Blue Alkaline Phosphatase Substrate and counterstained with haematoxylin. An antibody of the same isotype (Rat IgG2a; BD Biosciences) was used as the negative control.
Plaque and serum fatty acid binding protein concentration measurements
Adjacent segments to the culprit lesion served for protein isolation. Segments were processed according to a standardized protocol. Expression levels of FABP4 within the atherosclerotic specimens were quantified by ELISA measurements (SPI Bio, Montigny Le Bretonneux, France). All protein levels were adjusted for total protein concentration within the atherosclerotic plaque. For survival analyses, concentrations of FABP4 were divided into tertiles (ranges low, ,2.95 ng/mg, moderate 2.95-7.04 ng/mg, and high .7.04 ng/mg).
At the time of inclusion, blood was collected at the outpatient clinic prior to surgery from an unbiased subpopulation of 284 patients, since one of the participating hospitals did not routinely collect plasma samples. Blood was immediately centrifuged at 1850 g and subsequently isolated for FABP4 serum measurements. For survival analyses, FABP4 concentrations were arbitrarily divided into tertiles (cut-off values: ranges low, ,6.08 ng/mL, moderate 6.08-8.97 ng/mL, and high .8.97 ng/mL). 
Statistics and data analysis
Considering baseline characteristics, the relation between patient characteristics and FABP4 plaque levels were assessed by the nonparametric Mann-Whitney U test. In addition, differences in FABP4 expression levels between asymptomatic and symptomatic lesions prior to the operation were also assessed by the Mann-Whitney U test. Symptomatic lesions comprised plaques from patients who suffered from stroke or TIA. Asymptomatic lesions were regarded as plaques contributing to haemodynamic significant stenosis or those which were not directly related to clinical manifestation, such as a four-vessel disease. Correlations between the FABP4 levels and the quantitative macrophage and SMC assessments were analysed by non-parametric bivariate Spearman analyses. The association of FABP4 and all semiquantitative histological characteristics were analysed by using the Mann-Whitney U test. The association of FABP4 with the continuous histological plaque characteristics was expressed by a correlation coefficient and P-value. For the cross-sectional analyses, statistical significance was determined by P , 0.05.
Since atherosclerosis is a systemic disease affecting the arterial wall in multiple territories, we assume that a single atherosclerotic plaque phenotype holds information about plaque composition in another location of the arterial tree. Therefore, we used survival analyses. The Kaplan-Meier survival analysis was used to obtain the cumulative event rate. The survival curves were compared between the three tertile groups of FABP4. The Kaplan -Meier estimate of cumulative event rate at 1, 2, and 3 years after CEA, and the corresponding risk difference was calculated. To assess the independent relation of FABP4 expression with clinical outcome and to obtain the hazard ratio with a 95% confidence interval (95% CI), we used a Cox proportional hazards model. Baseline characteristics and medication significantly related to primary outcome in univariate regression analyses were included in the multivariate regression model. The threshold for statistical significance was a two-sided P , 0.05 (Table 5 ). SPSS 15.0 was used for all analyses (SPSS Inc., Chicago, IL, USA).
Results
In total, 561 consecutive patients (symptomatic: AFX n ¼ 74, TIA n ¼ 230, stroke n ¼ 135, asymptomatic: n ¼ 122) who underwent CEA between 24 March 2002 and 28 February 2006 were included.
Plaque and serum fatty acid binding protein levels and patients characteristics
Baseline characteristics are outlined in Table 1 . . ............ ............ ............ ............ ........... ............ ............ ............ ........... ............ ............ ............ ........... ............ .... The presence of intraplaque haemorrhage and the lipid core size were also significantly associated with FABP4 plaque expression levels ( Table 2 , both P , 0.001). Quantitative analyses of the SMC content in relation to FABP4 plaque levels revealed a negative association (R ¼ 20.21, P , 0.001), which was supported by the semiquantitative analyses ( Table 2 ). These observations suggest that FABP4 is associated with a more vulnerable plaque phenotype. Staining with monoclonal and polyclonal antibodies to detect FABP4 revealed a similar expression pattern. Immunohistochemical FABP4 staining was predominantly observed in the shoulder and cap areas of atheromatous plaques. Expression of FABP4 was observed in macrophages, which was confirmed by double immunohistochemical staining for FABP4 and CD68 ( Figure 1C) . Fatty acid binding protein-positive macrophages were predominantly macrophage foam cells (Figure 1) . Atherosclerotic plaques contain different types of macrophages, as has recently been demonstrated. 25 This could explain our observations that not every macrophage expresses FABP4 and suggests that macrophages may differentiate during the atherogenic process and selectively upregulate different biomarkers, such as matrix metalloproteinases. 25 Cross-sectional analyses of FABP4 serum levels with atherosclerotic plaque characteristics revealed no significant correlations ( Table 2 ). In addition, the correlation of FABP4 serum and plaque levels revealed a trend (Table 1) (R ¼ 0.10, P ¼ 0.080).
Plaque and serum fatty acid binding protein levels and clinical follow-up
During a mean follow-up time of 2.4 years (SD ¼ 1.0, maximum ¼ 4.8), 142 patients (25.3%) reached the primary endpoint ( Table 3) . Twenty-one patients died, 63 patients suffered from a non-fatal myocardial infarction or non-fatal stroke or underwent a coronary Table S3 ).
To exclude potential confounding of general cardiovascular risk factors and to show independency of plaque FABP4 expression levels with respect to primary outcome, we first performed univariate Cox regression analyses to determine the risk factors and types of medication related to primary outcome ( Table 5) . Besides gender, age, history of vascular intervention, and bilateral carotid stenosis, FABP4 was associated with primary outcome during 3 years of follow-up [1.33 (1.08-1.65), P ¼ 0.008]. Serological C-reactive protein levels were not associated with primary outcome [HR ¼ 1.00 (0.99-1.01), P ¼ 0.61]. Subsequently, we included the significant determinants from the univariate analyses, including FABP4 plaque expression levels into a multivariate Cox regression analysis to assess the independency of FABP4 to predict adverse cardiovascular events during follow-up. Besides plaque, FABP4, gender, and bilateral stenosis were independently related to clinical outcome. The hazard ratio for FABP4 persisted and was 1.33 with a 95% CI (1.08-1.65) (P ¼ 0.008) after adjustment of the baseline characteristics ( Table 5) . With respect to the third tertile in relation to the first tertile, the hazard ratio was 1.78 (1.15-2.72). For gender and the presence of bilateral stenosis, the hazard ratio was 1.97 (1.25-3.12) (P ¼ 0.004) and 2.08 (1.43-2.82) (P , 0.001), respectively.
Discussion
Atherosclerosis is an inflammatory disease of the arterial system. 12 Progression of atherosclerosis may result in acute clinical manifestations such as myocardial infarction and stroke. Inflammation and lipid accumulation are hallmarks of the vulnerable plaque and play essential roles in the pathogenesis of atherosclerosis and contribute to plaque destabilization. 26 -28 Adipocyte FABP4 integrates the inflammatory and lipid-mediated pathways and is considered to play an essential role in atherosclerotic plaque progression. Animal studies have shown that FABP4 is strongly associated with atherosclerotic plaque formation and vulnerable plaque features. 3, 4, 7 In addition, antagonizing FABP4 in atherosclerotic models results in reduced plaque progression. 9 However, studies investigating FABP4 expression in human atherosclerotic specimens are lacking. In the present study, we show in a large number of human atherosclerotic plaques that FABP4 can be recognized as a marker that is strongly associated with vulnerable plaque characteristics, since high local FABP4 expression levels are strongly associated with an inflammatory unstable plaque composition and with symptomatic lesions. More important, in addition to our cross-sectional observations, we performed a longitudinal study to assess the predictive value of plaque FABP4 expression for systemic cardiovascular outcome during 3-year follow-up. This is the first study showing that local FABP4 plaque levels are independently related to future systemic cardiovascular events. Adipocyte FABPs orchestrate the inflammatory and lipidmediated pathways that are critical components of vulnerable plaque development. 6 The primary role of FABP4 is reversibly binding saturated and unsaturated fatty acids and facilitating lipid transport to specific parts of the cell, such as mitochondria for oxidation, to the nucleus for lipid-mediated transcriptional regulation or outside the cell to signal in an autocrine or paracrine manner.
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Although FABP4 was traditionally regarded as a biomarker specifically expressed by differentiated adipocytes, fundamental mechanistic studies showed FABP4 expression in macrophages upon their differentiation from monocytes by the macrophage activators PPAR-g agonists and oxidized LDL. 5, 7, 29 Conversely, FABP4 regulates the activity of macrophages, since in FABP4 knockout macrophages particular inflammatory cytokine responses were suppressed. 6 Animal studies showed that FABP4 deficiency provided evident protection against atherosclerosis. Moreover, bone marrow transplantation studies demonstrated that the atheroprotective effects of FABP4 are considerably attributed to its actions in macrophages. 1, 4 In the present study, we hypothesized that FABP4 expression is present in human atherosclerotic lesions and that it is associated with a vulnerable plaque phenotype. The observations revealed that FABP4 expression within carotid atherosclerotic lesions correlated with unstable plaque characteristics, since it was associated with increased macrophage infiltration and increased lipid core size (.40%). These findings support the previous observations of Makowski et al. who showed correlations of FABP4 with foam cell development and an increase in inflammatory activity. 6, 10 In addition, collagen and SMC content were inversely related the FABP4 expression levels. FABP4 a marker for unstable plaques and CV events with increased inflammation. However, C-reactive protein levels were not associated with plaque FABP4 levels. Atherosclerosis is a systemic disease. The Athero-Express study was designed to study the hypothesis that, irrespective of the association with a vulnerable plaque phenotype, local plaque proteins hold information about the stability of the entire vascular system. We assume that potential plaque biomarkers within a single atherosclerotic plaque may show similarities among different vascular territories and predict systemic clinical cardiovascular outcome. Following this concept, we assessed the predictive value of local FABP4 expression in relation to systemic cardiovascular outcome in a longitudinal study. Survival analyses revealed a nearly two-fold increased event rate of patients with FABP4 expression levels in the third tertile in comparison with patients in the first tertile. Besides gender and bilateral carotid stenosis, increased expression of FABP4 was independently related with adverse systemic cardiovascular clinical outcome. The predictive value of FABP4 was independent of macrophage content or lipid content in the plaque which were both not predictive for adverse outcome. Age and serological C-reactive protein expression levels were not associated with adverse clinical outcome.
A correlation existed between macrophage content and FABP4; however, the relationship between FABP4 and outcome was not followed by a relation between macrophage content and outcome. 30 FABP was expressed in a subgroup of CD68-positive cells which revealed a foam cell phenotype. It could be suggested that the subgroup of macrophages expressing FABP4 play a more important role in plaque destabilization. We did not provide evidence that macrophages expressing FABP4 are predominantly associated with plaque rupture due to the inherent drawback of the cross-sectional design of the histological observations. This study does not challenge the general concept that macrophage infiltration is associated with local plaque vulnerability: The general concept correlates local plaque markers with local plaque vulnerability, while the present study has associated local plaque marker expression with systemic clinical outcome. Previous studies revealed that FABP4 is measurable as a circulating marker in serum 31, 32 and since plaque specimens are relatively more difficult to approach than plasma, we conducted an additional serum study to examine FABP4 expression levels in relation to cardiovascular outcome. Fatty acid binding protein serum levels were measured in an unbiased subpopulation of the cohort, since blood samples were not routinely collected in one of the hospitals. Serum expression levels were significantly increased in patients who suffered from cardiovascular events. However, we observed that serum expression levels were not linearly associated with cardiovascular outcome. Therefore, serum FABP4 expression appeared less consistent in predicting events compared with plaque samples. It is well established that FABP4 is expressed by adipocytes which are likely the major contributors of serological FABP4. It is therefore interesting to observe that both plaque and serological FABP4 levels revealed a relationship with adverse outcome. The absence of correlation between plaque and serological FABP4 levels may suggest that not just macrophage-derived FABP4 but also adipocytederived FABP4 could be associated with adverse outcomes. Moreover, our sample size merits careful consideration since the serological study may have been underpowered compared with the plaque study. Our cross-sectional and longitudinal data and previous animal studies suggest a role of FABP4 in atherosclerotic plaque development and subsequent clinical manifestations. Furuhashi and Hotamisligil 9 have recently shown that FABP4 may serve as a therapeutic target against severe atherosclerosis. Pharmaceutical inhibition of this potential marker showed that elimination reduces atherosclerotic plaque formation, since FABP4 inhibitors have shown to be effective drugs against atherogenesis and macrophage activity in vitro and in vivo. 8, 9 This underlines the clinical relevance of our histopathological observation. The evident associations of FABP4 expression levels in atherosclerotic plaques with clinical outcome during follow-up suggest that FABP4 may contribute to plaque destabilization and underlines the relevance of FABP4 inhibitors as potential drugs to reduce atherosclerotic plaque development and adverse manifestations. Our study comprises some limitations. Observations from previous human and animal studies suggest that the regulation and metabolic function of FABP4 are similar. However, a genetic variant in humans has been observed in the promoter region of the human FABP4 gene (T-87C). Patients with polymorphism of this locus demonstrated lower serum triglyceride levels and significantly reduced risk of coronary heart disease. 33 In the present cohort, we did not correlate these genetic deletions with FABP4 expression levels, which might have influenced the clinical outcome. In addition, FABP4 as a continuous variable revealed a less strong relation with systemic outcome, which may explain that the risk does not increase in a linear way with increasing FABP levels. From the current study, we may conclude that FABP4 expression levels within carotid atherosclerotic specimens are associated with unstable atherosclerotic plaques. Local FABP4 plaque levels are significantly related with adverse systemic clinical cardiovascular events during follow-up, independent from general or serological risk factors and medication use. However, application of the predictive value into the clinical setting merits careful consideration due to the relative low numbers of specimens and should be reproduced in a large cohort.
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